+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768200
  • Report
  • April 2019
  • Region: Global
  • 60 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Alvogen Inc
  • AzurRx BioPharma Inc
  • China Resources Group
  • Chr. Hansen Holding A/S
  • Hetero Drugs Ltd
  • MORE
The global clinical trial report- “2019 Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Vancomycin-Resistant Enterococcus faecium Infections. It presents in-depth analysis of Vancomycin-Resistant Enterococcus faecium Infections clinical trials across markets and companies. The research work is for providing complete understanding into trends in Vancomycin-Resistant Enterococcus faecium Infections.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Vancomycin-Resistant Enterococcus faecium Infections clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Vancomycin-Resistant Enterococcus faecium Infections

The research work is prepared through extensive and continuous research on Vancomycin-Resistant Enterococcus faecium Infections trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Vancomycin-Resistant Enterococcus faecium Infections patients are identified
  • The report includes panorama of Vancomycin-Resistant Enterococcus faecium Infections clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Vancomycin-Resistant Enterococcus faecium Infections clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Alvogen Inc
  • AzurRx BioPharma Inc
  • China Resources Group
  • Chr. Hansen Holding A/S
  • Hetero Drugs Ltd
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Region
2.2.2 Average Enrollment of Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Vancomycin-Resistant Enterococcus faecium Infections Treatment, 2019

3. Region wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials
3.1 Asia Pacific Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Country
3.2 Europe Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Country
3.3 North America Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Country
3.4 Middle East and Africa Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Country
3.5 South and Central America Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Country

4. Vancomycin-Resistant Enterococcus faecium Infections Clinical Trial Trends
4.1 Start Year wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials
4.2 Phase wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials
4.3 Trial Status wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials
4.4 Trial Type wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials

5. Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment Trends
5.1 Average Enrollment in Vancomycin-Resistant Enterococcus faecium Infections Trials by Year
5.2 Average Enrollment in Vancomycin-Resistant Enterococcus faecium Infections Trials by Phase
5.3 Average Enrollment in Vancomycin-Resistant Enterococcus faecium Infections Trials by Status
5.4 Average Enrollment in Vancomycin-Resistant Enterococcus faecium Infections Trials by Type of Trial

6. Companies Participating in Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials
6.1 Vancomycin-Resistant Enterococcus faecium Infections Trials by Sponsor Type
6.2 Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Vancomycin-Resistant Enterococcus faecium Infections Trials- Phase 1
7.2 Vancomycin-Resistant Enterococcus faecium Infections Trials- Phase 2
7.3 Vancomycin-Resistant Enterococcus faecium Infections Trials- Phase 3
7.4 Vancomycin-Resistant Enterococcus faecium Infections Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Figure 5: Europe - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Figure 7: North America - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Figure 9: Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Phase
Figure 10: Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Trial Status
Figure 11: Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Type
Figure 12: Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Sponsor Type
Figure 13: Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials by Leading Sponsors
Figure 14: Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment by Phase
Figure 15: Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment by Trial Status
Figure 16: Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment by Type
Figure 17: Vancomycin-Resistant Enterococcus faecium Infections- Average Enrolment by Type of Sponsors
Figure 18: Vancomycin-Resistant Enterococcus faecium Infections- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Table 5: Europe - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Table 7: North America - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Vancomycin-Resistant Enterococcus faecium Infections Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment by Phase
Table 15: Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment by Trial Status
Table 16: Vancomycin-Resistant Enterococcus faecium Infections Average Enrollment by Type
Table 17: Vancomycin-Resistant Enterococcus faecium Infections- Average Enrolment by Type of Sponsors
Table 18: Vancomycin-Resistant Enterococcus faecium Infections- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan Plc
  • Alvogen Inc
  • AzurRx BioPharma Inc
  • China Resources Group
  • Chr. Hansen Holding A/S
  • Hetero Drugs Ltd
  • LegoChem Biosciences Inc
  • MicuRx Pharmaceuticals Inc
  • Pfizer Inc
  • Worldwide Clinical Trials Holdings Inc
Note: Product cover images may vary from those shown
Adroll
adroll